GLP-1 After Bariatric Surgery: Research Needs
Okay, here’s a breakdown of the key details from the provided text, organized for clarity. I’ll cover the study’s focus, methods, participant characteristics, and key findings so far.
1. Study Focus/Main Point:
The study investigates the use of GLP-1 medications (like semaglutide, liraglutide, tirzepatide, etc.) after bariatric surgery (sleeve gastrectomy and Roux-en-Y gastric bypass).
It aims to understand real-world GLP-1 usage patterns post-surgery, as there’s growing interest in thes drugs for obesity treatment, but limited data on their role after weight loss surgery.
The study highlights that GLP-1s offer a potential option for patients who don’t achieve satisfactory weight loss or experience weight regain after bariatric surgery, especially given the limited alternatives before GLP-1s were available.
2. Study Methods:
Data Source: Electronic health record data from the TirNEtx global collaborative network.
Timeframe: January 1, 2015 - May 31, 2023.
Participants: Patients who underwent sleeve gastrectomy or Roux-en-Y gastric bypass and did not use GLP-1s in the 12 months before surgery.
Tracking: GLP-1 usage was tracked from the first prescription to the end of the study.
Covariates: Researchers considered factors like age, sex, race, ethnicity, marital status, location, pre- and post-surgical BMI, and pre-existing conditions (comorbidities).
Comorbidities assessed: type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, heart failure, asthma, steatotic liver disease, chronic kidney disease, polycystic ovarian syndrome, and gastroesophageal reflux disease.
3. Participant Characteristics (of the 112,858 included in the primary analysis):
Mean Age: 45.2 years
Gender: 78.9% female (88,994)
Race:
Asian: 1.1% (1210)
Black or African American: 22.1% (24,941)
White: 64.2% (72,423)
Other: 12.6% (14,284)
Ethnicity: 73.8% non-Hispanic/Latino (82230)
Surgery Type:
Sleeve Gastrectomy: 66.5% (75,033)
Roux-en-Y Gastric Bypass: 33.5% (37,825)
Pre-surgical BMI: Median of 42.0 (indicating meaningful obesity)
Common Comorbidities: Hypertension, obstructive sleep apnea, and dyslipidemia.
Pre-Surgery medication: 5.3% (5975) used non-GLP-1 anti-obesity medications.
4. Key Findings (so far):
GLP-1 Initiation Rate: 14% (15,749) of patients initiated GLP-1 use after bariatric surgery.
* Age Difference: Those who started GLP-1s post-surgery were slightly younger (mean age 44.9 years) than those who didn’t (mean age 45.2 years).
Let me know if you’d like me to elaborate on any specific aspect of the text, or if you have any questions about it.